Tetraphase Pharmaceuticals

Tetraphase Pharmaceutical is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic fluorocycline, as an intravenous, or IV, and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Company Growth (employees)
Type
Public
HQ
Watertown, US
Founded
2006
Size (employees)
66 (est)-4%
Website
tphase.com
Tetraphase Pharmaceuticals was founded in 2006 and is headquartered in Watertown, US

Tetraphase Pharmaceuticals Office Locations

Tetraphase Pharmaceuticals has an office in Watertown
Watertown, US (HQ)
110 480 Arsenal St

Tetraphase Pharmaceuticals Data and Metrics

Tetraphase Pharmaceuticals Financial Metrics

Tetraphase Pharmaceuticals's revenue was reported to be $1.5 m in Q1, 2017
USD

Revenue (Q1, 2017)

1.5 m

Net income (Q1, 2017)

(29.5 m)

EBIT (Q1, 2017)

(29.6 m)

Market capitalization (15-Aug-2017)

228.5 m

Cash (31-Mar-2017)

128.2 m
Tetraphase Pharmaceuticals's current market capitalization is $228.5 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

18.3 m9.1 m11.7 m5.1 m

Revenue growth, %

(50%)28%(56%)

Operating expense total

131.1 m74.9 m94.7 m83 m

EBIT

(112.8 m)(65.8 m)(83 m)(77.8 m)

EBIT margin, %

(617%)(723%)(710%)(1513%)

Interest expense

1.7 m1 m231 k231 k

Interest income

10 k17 k42 k350 k

Net Income

(119.7 m)(66.7 m)(83.2 m)(77.5 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

1.3 m2.3 m3 m3.3 m2.9 m2 m1.2 m850 k1.5 m

R&D expense

16.5 m13.2 m18.9 m22.9 m17 m13.5 m13.7 m17.2 m25.9 m

General and administrative expense

2.9 m3.1 m4.9 m6.5 m3.9 m5.3 m4.8 m4.9 m5.1 m

Operating expense total

19.5 m16.3 m23.8 m29.4 m20.9 m18.8 m18.5 m22 m31.1 m

EBIT

(18.2 m)(14 m)(20.8 m)(26.1 m)(18.1 m)(16.8 m)(17.3 m)(21.2 m)(29.6 m)

EBIT margin, %

(1426%)(609%)(688%)(779%)(632%)(857%)(1389%)(2494%)(1993%)

Interest expense

(282 k)(229 k)(230 k)

Interest income

4 k3 k6 k

Net Income

(18.5 m)(14.2 m)(21 m)(26 m)(18 m)(16.7 m)(17.2 m)(21.1 m)(29.5 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

102.7 m121 m205.9 m142.1 m

Accounts Receivable

1.7 m3.5 m4.2 m1.8 m

Inventories

1 m2.1 m3.7 m6.6 m

Current Assets

105.4 m126.6 m213.8 m150.5 m

PP&E

235 k300 k943 k1.1 m

Total Assets

105.9 m127.2 m214.9 m151.7 m

Accounts Payable

1.9 m4.1 m2.9 m2.6 m

Current Liabilities

13.2 m17.3 m10.7 m11.5 m

Additional Paid-in Capital

207.5 m295 m473.7 m487.1 m

Retained Earnings

(186.5 m)(269.7 m)(347.1 m)

Total Equity

87.8 m108.6 m204.1 m140.1 m

Financial Leverage

1.2 x1.2 x1.1 x1.1 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

75.4 m56 m260.3 m242.1 m222.5 m189.9 m178.3 m162.1 m128.2 m

Accounts Receivable

1.3 m2 m5.5 m3.4 m3.1 m3.8 m3 m745 k1.7 m

Current Assets

78.5 m60.5 m268.9 m248.4 m228.1 m200.7 m186.5 m169.5 m133.7 m

PP&E

237 k314 k317 k946 k869 k948 k982 k932 k1.5 m

Total Assets

79 m61.1 m269.6 m249.6 m229.2 m201.9 m187.7 m170.6 m135.4 m

Accounts Payable

6.7 m3.7 m5.6 m5.8 m1.7 m1.5 m2.5 m3.6 m3.6 m

Current Liabilities

17.3 m13.2 m15.7 m15.7 m10.6 m10.2 m10.3 m10.9 m16.2 m

Additional Paid-in Capital

210.1 m211.4 m461.3 m467.4 m469.9 m477.9 m480.8 m484.2 m495.5 m

Retained Earnings

(151.7 m)(165.9 m)(207.4 m)(233.5 m)(251.5 m)(286.4 m)(303.6 m)(324.7 m)(376.6 m)

Total Equity

58.4 m45.5 m253.9 m233.9 m218.4 m191.5 m177.2 m159.6 m119 m

Financial Leverage

1.4 x1.3 x1.1 x1.1 x1 x1.1 x1.1 x1.1 x1.1 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(29.6 m)(66.7 m)(83.2 m)(77.5 m)

Depreciation and Amortization

129 k124 k193 k282 k

Accounts Receivable

746 k(1.8 m)(693 k)2.4 m

Inventories

(154 k)(1.2 m)(1.5 m)

Accounts Payable

310 k2.2 m(1.2 m)(302 k)

Cash From Operating Activities

(24.5 m)(57.6 m)(76.7 m)(63.8 m)

Purchases of PP&E

(129 k)(191 k)(838 k)(393 k)

Cash From Investing Activities

(129 k)(191 k)(838 k)(393 k)

Cash From Financing Activities

118.3 m76.1 m162.4 m333 k

Interest Paid

1.1 m945 k363 k363 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(18.5 m)(14.2 m)(21 m)(26 m)(18 m)(16.7 m)(17.2 m)(21.1 m)(29.5 m)

Accounts Receivable

1.3 m2 m5.5 m3.4 m3.1 m3.8 m3 m745 k1.7 m

Accounts Payable

6.7 m3.7 m5.6 m5.8 m1.7 m1.5 m2.5 m3.6 m3.6 m
USDY, 2017

Revenue/Employee

22 k

Financial Leverage

1.1 x

Tetraphase Pharmaceuticals Market Value History

Traffic Overview of Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals Online and Social Media Presence

Tetraphase Pharmaceuticals Company Life and Culture

You may also be interested in